Table II.
Univariate analysis of baseline characteristics of patients and lesions in low-MPV compared with high-MPV cohorts.
| Preoperative characteristics | MPV ≤10.3 (×10−15 l) (n=77) | MPV >10.3 (×10−15 l) (n=88) | P-value |
|---|---|---|---|
| Age, mean ± SD | 60.8±9.96 | 64.7±10.8 | 0.01 |
| Male, n (%) | 54 (70.1) | 55 (62.5) | 0.30 |
| Female, n (%) | 23 (29.9) | 33 (37.5) | 0.30 |
| Performance status | |||
| KPS, median (IQR) | 80 (70–90) | 80 (70–90) | 0.45 |
| Inflammation markers | |||
| WBC, 109/l | 10.3±3.88 | 10.2±3.7 | 0.76 |
| Neutrophils, 109/l | 7.98±4.01 | 8.20±3.97 | 0.73 |
| Pathology | |||
| Presence of central necrosis (n, %) | 68 (90.6) | 73 (85.8) | 0.35 |
| Midline shift > 5 mm | 27 (36.4) | 39 (45.3) | 0.25 |
| Mean FLAIR volume (cm3) | 92.3±54.2 | 105.2±63.2 | 0.17 |
| Mean T1-CE volume (cm3) | 31.6±25.9 | 37.6±27.4 | 0.07 |
| Presence of satellite FLAIR lesions (n, %) | 16 (21.6) | 11 (12.9) | 0.14 |
| Genetics | |||
| MGMT methylation, (n, %) | 23 (35.9) | 26 (37.6) | 0.85 |
| p53 (% immunoreactive cells) | 0.22±0.26 | 0.18±0.23 | 0.38 |
| Ki67 (% immunoreactive cells) | 0.31±0.18 | 0.31±0.19 | 0.92 |
| Mean daily dose pre-operative dexamethasone (mg) | 5.32±7.7 | 6.12±8.1 | 0.58 |
WBC, white blood cell count; KPS, Karnofsky performance status; MGMT met, MGMT methylation status; SD, standard deviation; IQR, interquartile range.